Form4insider filings, from the source

SEC Form 4 · accession 0001140361-17-032479

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jacob Van Naarden
Officer — Chief Business Officer
Period of report
Aug 14, 2017
Accepted (ET)
Aug 16, 2017 · 5:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockAug 14, 2017M1,541$3.648A1,541D
Common StockF2,F3Aug 14, 2017S1,000$73.545D541D
Common StockF2,F4Aug 14, 2017S541$74.074D0D
Common StockAug 15, 2017M1,541$3.648A1,541D
Common StockF2,F5Aug 15, 2017S1,541$73.4158D0D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F6$3.648Aug 14, 2017M1,541D—Jun 18, 2024Common Stock1,541127,412D
Employee Stock Option (right to buy)F6$3.648Aug 15, 2017M1,541D—Jun 18, 2024Common Stock1,541125,871D

Explanation of responses